Successful FDA Submission
Spectral AI completed its FDA submission for the DeepView System in the second quarter of 2025, marking a significant milestone in the company's development.
Strong Financial Position
The company completed a debt financing agreement with Avenue Venture Opportunities Fund II for up to $15 million and raised $2.7 million in equity financing, leading to a cash balance of over $10 million at the end of June 2025.
Reduction in General and Administrative Expenses
General and administrative expenses were reduced from $5.8 million in Q2 2024 to $4.4 million in Q2 2025, reflecting continued focus on operating efficiencies.
Decreased Net Loss for the First Half of 2025
Despite a larger warrant liability, the company reported a net loss of $5.1 million for the first half of 2025, down from $6.1 million in the same period of 2024.